Aldosterone synthase inhibitors for the treatment of cardiovascular disease - PubMed
3 hours ago
- #Hypertension treatment
- #Aldosterone
- #Cardiovascular disease
- Aldosterone plays a key role in blood pressure regulation through mineralocorticoid receptor and rapid signaling pathways.
- Excess aldosterone contributes to cardiovascular and renal injury in conditions like resistant hypertension, primary aldosteronism, and heart failure.
- Mineralocorticoid receptor antagonists are standard therapy but leave residual cardiovascular risk by not fully blocking aldosterone's effects.
- Aldosterone synthase inhibitors represent a novel approach that reduces aldosterone levels and blood pressure in clinical trials.
- Further research is needed on long-term safety, comparison with existing therapies, and impact on cardiovascular outcomes.